Comparative Pharmacology
Head-to-head clinical analysis: BUTABARB versus BUTISOL SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTABARB versus BUTISOL SODIUM.
BUTABARB vs BUTISOL SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Barbiturate that binds to GABA-A receptor subunits, potentiating GABAergic inhibition by increasing chloride ion conductance and reducing neuronal excitability.
Enhances GABA-A receptor activity, increasing chloride ion conductance and causing central nervous system depression.
15-30 mg orally 3-4 times daily as needed; maximum 200 mg/day. IV/IM: 50-200 mg for sedation.
Oral: 50-100 mg 3-4 times daily; maximum 600 mg daily.
None Documented
None Documented
Terminal elimination half-life is 30-60 hours (mean ~40 hours) in adults with normal renal and hepatic function. Longer in elderly or patients with liver disease.
Clinical Note
moderateButabarbital + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Fluticasone propionate."
Clinical Note
moderateButabarbital + Haloperidol
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Haloperidol."
Clinical Note
moderateButabarbital + Clemastine
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Clemastine."
Clinical Note
moderateTerminal elimination half-life: 40-70 hours (mean 60 h) in adults; prolonged in elderly, hepatic impairment, and neonates (up to 100 h). Clinical context: Accumulation occurs with repeated dosing.
Renal excretion of unchanged drug and metabolites. Approximately 70-80% of a dose is eliminated in urine as metabolites (hydroxy and glucuronide conjugates) and <5% as parent drug. Minimal biliary/fecal elimination (<5%).
Primarily hepatic metabolism (80%) with renal excretion of inactive metabolites (<30% unchanged). Less than 1% excreted in feces.
Category C
Category C
Barbiturate
Barbiturate
Butabarbital + Venlafaxine
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Venlafaxine."